REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

Inclusion Criteria:

• Patients with acute myocardial infarction (ST elevation in at least 2 leads >= 0.2 mVin V1,V2 or V3 or >= 0.1 mV in other leads), treated by one of the followingprocedures

• Either acute PCI with stent implantation within 24 hours after symptom onset or

• treatment with thrombolysis within 12 hours of symptom onset followed by PCI withstent implantation within 24 hours after thrombolysis.

• Acute PCI / stent implantation has been successful (residual stenosis visually < 30%and TIMI flow >= 2).

• At the time of inclusion patient does no longer require i.v. catecholamines ormechanical hemodynamic support (aortic balloon pump)

• Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction <= 45% on visual estimation).

• Maximal CK elevation >= 400 U/l (measured at 37° C) with significant MB fraction > 6%

• Age 18 - 80 Years

• Written informed consent

Exclusion Criteria:

• Regional wall motion abnormality outside the area involved in the index acutemyocardial infarction.

• Need to revascularize additional vessels, outside the infarct artery.

• Arteriovenous malformations or aneurysms

• Active infection (CRP > 10 mg/dl) now, or fever or diarrhea within last 4 weeks.

• Chronic inflammatory disease

• HIV infection or active hepatitis

• Neoplastic disease without documented remission within the past 5 years.

• Cerebrovascular insult within 3 months

• Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy

• Significant liver disease (GOT > 2x upper limit) or spontaneous INR > 1,5)

• Anemia (hemoglobin < 8.5 mg/dl)

• Platelet count < 100.000/µl

• Hypersplenism

• Known allergy or intolerance to clopidogrel, heparin or abciximab.

• History of bleeding disorder

• Gastrointestinal bleeding within 3 months

• Major surgical procedure or traumata within 2 months

• Uncontrolled hypertension

• Pregnancy

• Mental retardation

• Previously performed stem / progenitor cell therapy

• Participation in another clinical trial within the last 30 days.